Maintenance warfarin dose varies according to two haplotypes of the vitamin K epoxide reductase gene

Future Cardiology

Volumn 2, Issue 1, 2006, Pages 29-32

  John, Jerry M ^a   Herrington, David M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic anticoagulation; Haplotype; Pharmacogenomics; Race single nucleotide polymorphism; Warfarin dosing

Indexed keywords

MENADIONE EPOXIDE; OXIDOREDUCTASE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VARIANCE;

EID: 33646554175     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.1.29     Document Type: Article

References (7)

1. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
2. Panneerselvam S, Baglin C, Lefort W et al.: Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br. J. Haematol. 103(2), 422-424 (1998).
3. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13), 1690-1698 (2002).
4. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005).
5. Margaglione M, Colaizzo D, D'Andrea G et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84(5), 775-778 (2000).
6. Althal GP, Day CP, Kesteven PJL et al.: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999).
7. Taube J, Halsall D, Baglin T et al.: Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96(5), 1816-1819 (2000).